Prothena reported $1.01M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 480.13M 15.88M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Exelixis USD 658.69M 30M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Prothena USD 1.01M 50.07M Jun/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026